1. Martelli, M, Ferreri, AJM, Agostinelli, C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87:146-171.
Google Scholar | Crossref | Medline2. Swerdlow, SH, Campo, E, Harris, NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Publications; 2008. Accessed August 2, 2021. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017
Google Scholar3. Hans, CP, Weisenburger, DD, Greiner, TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82.
Google Scholar | Crossref | Medline4. Bain, BJ, Catovsky, D. The leukaemic phase of non-Hodgkin’s lymphoma. J Clin Pathol. 1995;48:189-193.
Google Scholar | Crossref | Medline5. Pires, PP, Kanegae, MY, Rays, J, et al. Diffuse large B-cell lymphoma presenting in the leukemic phase. Autopsy Case Rep. 2016;6:41-45.
Google Scholar | Crossref | Medline6. Wong, E, Juneja, S. Diffuse large B-cell lymphoma in leukemic phase with flower cell morphology. Blood. 2014;123:3378.
Google Scholar | Crossref | Medline7. Harada, S, Suzuki, R, Uehira, K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13:1441-1447.
Google Scholar | Crossref | Medline8. Niitsu, N, Okamoto, M, Tamaru, J-I, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21:2069-2074.
Google Scholar | Crossref | Medline9. Tagawa, H, Suguro, M, Tsuzuki, S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005;106:1770-1777.
Google Scholar | Crossref | Medline10. Yamaguchi, M, Seto, M, Okamoto, M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99:815-821.
Google Scholar | Crossref | Medline11. Zhao, P, Li, L, Zhou, S, et al. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematol Oncol. 2019;37:360-367.
Google Scholar | Crossref | Medline12. Miyazaki, K, Yamaguchi, M, Suzuki, R, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22:1601-1607.
Google Scholar | Crossref | Medline13. Miyazaki, K, Asano, N, Yamada, T, et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica. 2019;105:2308-2315.
Google Scholar | Crossref14. Chandrakasan, S, Filipovich, AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163:1253-1259.
Google Scholar | Crossref | Medline15. Schram, AM, Berliner, N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125:2908-2914.
Google Scholar | Crossref | Medline16. Han, S-M, Teng, C-L, Hwang, G-Y, et al. Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture. J Chin Med Assoc. 2008;71:210-213.
Google Scholar | Crossref | Medline17. Dasgupta, T, Coombes, B, Brasfield, RD. Primary malignant neoplasms of the spleen. Surg Gynecol Obstet. 1965;120:947-960.
Google Scholar | Medline18. Ismail, S, Ali, F, Ajamieh, H, et al. Primary splenic anaplastic variant of diffuse large B-cell lymphoma: a case report. J Med Case Reports. 2021;15:227.
Google Scholar | Crossref | Medline19. Skarin, AT, Davey, FR, Moloney, WC. Lymphosarcoma of the spleen. Results of diagnostic splenectomy in 11 patients. Arch Intern Med. 1971;127:259-265.
Google Scholar | Crossref | Medline20. Vick, EJ, Patel, K, Prouet, P, et al. Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy. Blood Adv. 2017;1:779-791.
Google Scholar | Crossref | Medline